EpiPen's sporadic price hike evoked shock and outrage from the public. Now, regulatory filings reveal that the hike was triggered by executives who wanted to jack up earnings per share.
EpiPen's sporadic price hike evoked shock and outrage from the public. Now, regulatory filings reveal that the hike was triggered by executives who wanted to jack up earnings per share.
Please to comment